CTOs on the Move

Inscripta, Inc

www.inscripta.com

 
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Inscripta, Inc raised $55.5M on 02/28/2018
Inscripta, Inc raised $30M on 12/18/2018
Inscripta, Inc raised $20M on 04/04/2019

Similar Companies

Chroma Medicine

Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.

Xigo Nanotools

Xigo Nanotools is a Morganville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioCentriq

BioCentriq was founded in 2018 and is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Our ISO-7 certified GMP clinical manufacturing facility is in Newark, NJ. At this facility, we manufacture autologous and allogeneic cell therapies, gene therapies and provide analytical and quality services across several cell types. We offer viral vector production, cell and viral banking and upstream and downstream processing. Additionally, we have the capabilities to manufacture immunotherapies, including monoclonal antibodies and proteins, and vaccines. Our facilities provide full customer access to work in hybrid teams from tech transfer through GMP clinical production. BioCentriq has a BSL-2 certified process development facility located in South Brunswick, NJ to accelerate scale-up and translation activities. We are vendor and technology agnostic and work with our clients to leverage the optimal technology platform for your product through the development process. In support of our full suite of process development and clinical manufacturing services, the team at BioCentriq offers pre-defined and custom workforce development programs as well as full access to our centers during projects in a unique collaborative approach with our expert scientists to knowledge transfer.

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.

Engage Therapeutics

Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.